trending Market Intelligence /marketintelligence/en/news-insights/trending/-qq6Q5FKfP7uhOUrdZvObA2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Everstone to invest US$50M in KKR-backed Slayback Pharma

Blog

Needham & Company is Now Available in the S&P Global Market Intelligence Aftermarket Research Collection

Blog

Banking Essentials Newsletter - February Edition, Part 2

Podcasts

StreetTalk – Episode 74: Investor sees legs in strong credit performance, US bank stock rally

Blog

Street Talk – Episode 74: Investor sees legs in strong credit performance, US bank stock rally


Everstone to invest US$50M in KKR-backed Slayback Pharma

Asia-focused private equity firm Everstone Capital Asia Pte Ltd. agreed to invest up to US$50 million in a series B funding round in KKR & Co. Inc.-backed pharmaceutical company Slayback Pharma LLC.

Along with the investment, Everstone's managing directors Arjun Oberoi and Puncham Mukim will join Slayback's board.

The capital will be used to expand and accelerate Slayback's differentiated line of pharmaceutical products.

KKR invested US$60 million in Slayback in December 2016.